N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis

N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis

Opis bibliograficzny
Główni autorzy:	Kasperzyk, J, d'Azzo, A, Platt, F, Seyfried, T
Format:	Conference item
Wydane:	2004

Podobne zapisy

N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
od: Kasperzyk, J, i wsp.
Wydane: (2004)

"Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice" (vol 46, pg 744, 2004)
od: Kasperzyk, J, i wsp.
Wydane: (2005)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
od: Baek, R, i wsp.
Wydane: (2008)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
od: Baek, R, i wsp.
Wydane: (2004)

Erratum: Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice (Journal of Lipid Research (April 2004) 46 (744-751))
od: Kasperzyk, J, i wsp.
Wydane: (2005)

Substrate deprivation therapy reduces brain ganglioside content and GM1 in neonatal storage disease mice
od: Kasperzyk, J, i wsp.
Wydane: (2002)

Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
od: Baek, R, i wsp.
Wydane: (2005)

Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
od: Jeyakumar, M, i wsp.
Wydane: (2003)

Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
od: Elliot-Smith, E, i wsp.
Wydane: (2008)

Therapeutic assessment of substrate deprivation using NB-DGJ in GM1 storage disease mice
od: Seyfried, T, i wsp.
Wydane: (2003)

N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours.
od: Ranes, M, i wsp.
Wydane: (2001)

Combined deficiencies of endosomal ganglioside neuraminidases 3 and 4 in mice cause lysosomal GM3 gangliosidosis
od: Pshezhetsky, A, i wsp.
Wydane: (2017)

Combined deficiencies of endosomal ganglioside neuraminidases 3 and 4 in mice cause lysosomal GM3 gangliosidosis
od: Pshezhetsky, A, i wsp.
Wydane: (2017)

Altered expression of ganglioside metabolizing enzymes results in GM3 ganglioside accumulation in cerebellar cells of a mouse model of juvenile neuronal ceroid lipofuscinosis
od: Somogyi, A, i wsp.
Wydane: (2018)

Effects of substrate deprivation therapy on brain lipids in neonatal GML storage disease mice
od: Kasperzyk, J, i wsp.
Wydane: (2003)

Therapeutic developments for neurodegenerative GM1 gangliosidosis
od: Dorian Foster, i wsp.
Wydane: (2024-04-01)

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
od: Andersson, U, i wsp.
Wydane: (2004)

GM1 Gangliosidosis Type 1 and Mongolian Spots
od: J Gordon Millichap
Wydane: (2013-06-01)

Altered GM1 catabolism affects NMDAR-mediated Ca2+ signaling at ER-PM junctions and increases synaptic spine formation in a GM1-gangliosidosis model
od: Jason A. Weesner, i wsp.
Wydane: (2024-05-01)

GM1 ganglioside-independent intoxication by Cholera toxin
od: Cervin, J, i wsp.
Wydane: (2018)

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
od: Andersson, U, i wsp.
Wydane: (2000)

Persistent elevations of alkaline phosphatase as an early indicator of GM1 gangliosidosis
od: Iskren Menkovic, i wsp.
Wydane: (2025-03-01)

GM1 - gangliosidosis in a Nigerian infant: A case report
od: Abdullahi M Sakina, i wsp.
Wydane: (2021-03-01)

Case report: Preimplantation genetic testing for infantile GM1 gangliosidosis
od: Valeria A. Zagaynova, i wsp.
Wydane: (2024-02-01)

Genetic Analysis of Undiagnosed Juvenile GM1-Gangliosidosis by Microarray and Exome Sequencing
od: Ahmed Bouhouche, i wsp.
Wydane: (2018-01-01)

GM2-gangliosidosis, type I (Tay – Sachs disease) in the pediatrician practice
od: Natalia V. Zhurkova, i wsp.
Wydane: (2021-01-01)

Extensive telangiectasias and mongolian spots: A clue towards GM1-gangliosidosis
od: Sachin Gupta, i wsp.
Wydane: (2023-01-01)

Elevation of ganglioside degradation pathway drives GM2 and GM3 within amyloid plaques in a transgenic mouse model of Alzheimer's disease
od: Wenxuan Wang, i wsp.
Wydane: (2025-02-01)

Pathological findings of central nervous system, two GM1 gangliosidosis autopsy cases
od: Doğuş Özdemir Kara, i wsp.
Wydane: (2019-12-01)

Clinical and imaging predictors of late‐onset GM2 gangliosidosis: A scoping review
od: Neha P. Godbole, i wsp.
Wydane: (2024-01-01)

NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines
od: Luis E. Fernandez, i wsp.
Wydane: (2010-01-01)

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
od: Melanie Alpaugh, i wsp.
Wydane: (2017-10-01)

GM2 Gangliosidosis (Tay-Sachs Disease), type I, Infantile Form: Clinical Case
od: Artem A. Babkin, i wsp.
Wydane: (2024-09-01)

Re: “Molecular analysis of 9 unrelated families presenting with juvenile and chronic GM1 gangliosidosis”
od: Carlos Eduardo Steiner, i wsp.
Wydane: (2024-02-01)

Mutations in B4GALNT1 (GM2 synthase) underlie a new disorder of ganglioside biosynthesis
od: Harlalka, G, i wsp.
Wydane: (2013)

GM1 Ganglioside Promotes Osteogenic Differentiation of Human Tendon Stem Cells
od: Sonia Bergante, i wsp.
Wydane: (2018-01-01)

Infantile Gangliosidosis
od: J Gordon Millichap
Wydane: (1988-08-01)

Quantitative reliability assessment of brain MRI volumetric measurements in type II GM1 gangliosidosis patients
od: Christopher Zoppo, i wsp.
Wydane: (2024-09-01)

Enhanced Susceptibility to Chemoconvulsant-Induced Seizures in Ganglioside GM3 Synthase Knockout Mice
od: Fu-Lei Tang, i wsp.
Wydane: (2020-07-01)

Chimeric antigen receptor T cells targeting the GM3(Neu5Gc) ganglioside
od: Julia Heinzelbecker, i wsp.
Wydane: (2024-02-01)